Literature DB >> 24906877

Prognostic impact of angiopoietin-2 in multiple myeloma.

Constantina A Pappa1, Michael G Alexandrakis, Anna Boula, Aspasia Thanasia, Ioannis Konsolas, Athanasios Alegakis, George Tsirakis.   

Abstract

PURPOSE: Angiogenesis is an essential process for the expansion of multiple myeloma (MM). Angiopoietin-2 (Ang-2), Ang-1 and their receptor possess important roles in this procedure. The aim of the study was to measure serum levels of Ang-2 along with known markers of angiogenesis and to estimate their prognostic impact on the survival.
METHODS: Bone marrow microvascular density (MVD), estimated by CD31, and circulating levels of known angiogenic factors Ang-2, interleukin-6, soluble CD105 and platelet-derived growth factor-AB, measured by ELISA, were measured in 77 newly diagnosed patients with active MM and in 57 of them who responded to chemotherapy.
RESULTS: All measured parameters were increased in MM patients, were also increasing in advanced disease and decreased after effective treatment. Ang-2 correlated positively with the other angiogenic factors and MVD. Moreover, Ang-2 values above the median were accompanied by worse survival.
CONCLUSION: Ang-2 correlates strongly with the angiogenic process and its serum levels are importantly prognostic for survival, highlighting the role of angiopoietins pathway in the biology of MM.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24906877     DOI: 10.1007/s00432-014-1731-2

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  25 in total

1.  The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism.

Authors:  Marion Scharpfenecker; Ulrike Fiedler; Yvonne Reiss; Hellmut G Augustin
Journal:  J Cell Sci       Date:  2005-02-01       Impact factor: 5.285

Review 2.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.

Authors:  J Holash; S J Wiegand; G D Yancopoulos
Journal:  Oncogene       Date:  1999-09-20       Impact factor: 9.867

3.  Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma.

Authors:  George Tsirakis; Constantina A Pappa; Peggy Kanellou; Maria A Stratinaki; Athina Xekalou; Fotios E Psarakis; George Sakellaris; Athanasios Alegakis; Efstathios N Stathopoulos; Michael G Alexandrakis
Journal:  Hematol Oncol       Date:  2011-09-14       Impact factor: 5.271

Review 4.  Angiogenesis and antiangiogenic therapy in hematologic malignancies.

Authors:  Xunwei Dong; Zhong Chao Han; Renchi Yang
Journal:  Crit Rev Oncol Hematol       Date:  2006-12-22       Impact factor: 6.312

5.  Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.

Authors:  Luca Agnelli; Silvio Bicciato; Michela Mattioli; Sonia Fabris; Daniela Intini; Donata Verdelli; Luca Baldini; Fortunato Morabito; Vincenzo Callea; Luigia Lombardi; Antonino Neri
Journal:  J Clin Oncol       Date:  2005-08-29       Impact factor: 44.544

Review 6.  Mechanisms of normal and tumor-derived angiogenesis.

Authors:  Michael Papetti; Ira M Herman
Journal:  Am J Physiol Cell Physiol       Date:  2002-05       Impact factor: 4.249

7.  Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis.

Authors:  Nicola Giuliani; Simona Colla; Mirca Lazzaretti; Roberto Sala; Giovanni Roti; Cristina Mancini; Sabrina Bonomini; Paolo Lunghi; Magda Hojden; Giovenzio Genestreti; Mirija Svaldi; Paolo Coser; Pier Paolo Fattori; Gabriella Sammarelli; Gian Carlo Gazzola; Regis Bataille; Camillo Almici; Cecilia Caramatti; Lina Mangoni; Vittorio Rizzoli
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

Review 8.  CD105 is important for angiogenesis: evidence and potential applications.

Authors:  Sarah E Duff; Chenggang Li; John M Garland; Shant Kumar
Journal:  FASEB J       Date:  2003-06       Impact factor: 5.191

9.  Serum levels of angiopoietin-2 are associated with the growth of multiple myeloma.

Authors:  Constantina A Pappa; George Tsirakis; Panagiotis Samiotakis; Maria Tsigaridaki; Athanasios Alegakis; Nectaria Goulidaki; Michael G Alexandrakis
Journal:  Cancer Invest       Date:  2013-06-11       Impact factor: 2.176

10.  Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients.

Authors:  C A Pappa; M G Alexandrakis; A Boula; F E Psarakis; A Kolovou; V Bantouna; E Stavroulaki; G Tsirakis
Journal:  Hematol Oncol       Date:  2013-04-11       Impact factor: 5.271

View more
  8 in total

1.  Elevated Angiopoietin-2 Level in Patients With Continuous-Flow Left Ventricular Assist Devices Leads to Altered Angiogenesis and Is Associated With Higher Nonsurgical Bleeding.

Authors:  Corey E Tabit; Phetcharat Chen; Gene H Kim; Savitri E Fedson; Gabriel Sayer; Mitchell J Coplan; Valluvan Jeevanandam; Nir Uriel; James K Liao
Journal:  Circulation       Date:  2016-06-28       Impact factor: 29.690

Review 2.  Therapeutic targeting of the angiopoietin-TIE pathway.

Authors:  Pipsa Saharinen; Lauri Eklund; Kari Alitalo
Journal:  Nat Rev Drug Discov       Date:  2017-05-19       Impact factor: 84.694

3.  Interrelationship between angiogenesis, inflammation and oxidative stress in Indian patients with multiple myeloma.

Authors:  S Joshi; N Gupta; R Khan; R Kumar; M Sharma; L Kumar; A Sharma
Journal:  Clin Transl Oncol       Date:  2015-07-14       Impact factor: 3.405

Review 4.  The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.

Authors:  Nikolaos Giannakoulas; Ioannis Ntanasis-Stathopoulos; Evangelos Terpos
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

Review 5.  Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression.

Authors:  Patrizia Mondello; Salvatore Cuzzocrea; Michele Navarra; Michael Mian
Journal:  Oncotarget       Date:  2017-03-21

Review 6.  Ang2-Targeted Combination Therapy for Cancer Treatment.

Authors:  Na Liu; Mengfang Liu; Shengqiao Fu; Jinglei Wang; Haowen Tang; Adamu Danbala Isah; Deyu Chen; Xu Wang
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

7.  High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma.

Authors:  Normann Steiner; Roman Hajek; Sabina Sevcikova; Bojana Borjan; Karin Jöhrer; Georg Göbel; Gerold Untergasser; Eberhard Gunsilius
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

8.  Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma.

Authors:  Ga-Young Song; Sung-Hoon Jung; Kihyun Kim; Seok Jin Kim; Sang Eun Yoon; Ho Sup Lee; Mihee Kim; Seo-Yeon Ahn; Jae-Sook Ahn; Deok-Hwan Yang; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  BMC Cancer       Date:  2020-08-24       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.